Lifetime Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Lifetime Sciences's estimated annual revenue is currently $4M per year.
- Lifetime Sciences's estimated revenue per employee is $155,000
Employee Data
- Lifetime Sciences has 26 Employees.
- Lifetime Sciences grew their employee count by 8% last year.
Lifetime Sciences's People
Name | Title | Email/Phone |
---|---|---|
1 | Lead Special Analyst in Molecular Biology | Reveal Email/Phone |
2 | Special Analyst | Reveal Email/Phone |
3 | Lead Phlebotomist | Reveal Email/Phone |
4 | Software Developer | Reveal Email/Phone |
Lifetime Sciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 11 | 0% | N/A | N/A |
#2 | $5M | 32 | 14% | N/A | N/A |
#3 | $3.6M | 23 | 5% | N/A | N/A |
#4 | $1.1M | 7 | -22% | N/A | N/A |
#5 | $1.7M | 11 | 0% | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $6M | 39 | 50% | N/A | N/A |
#8 | $0.9M | 6 | 0% | N/A | N/A |
#9 | $4.8M | 31 | -6% | N/A | N/A |
#10 | $1.9M | 12 | 0% | N/A | N/A |
What Is Lifetime Sciences?
Lifetime Sciences (formerly MyGenetx) is a CLIA-certified and CAP accredited lab focused on molecular and advanced diagnostic testing. Lifetime Sciences is the primary resource for transitioning and implementing precision guided medicine. Our medical team consists of experts in research and clinical product development for genetics. MyPGtâ„¢ A pharmacogenetic panel to determine how you metabolize your medication(s). Traditional "one size fits all" dosing strategies can cause adverse drug reactions or drug inefficacy. MyHap2â„¢ A proprietary genetic test to determine heart attack risk in patients with diabetes.
keywords:N/AN/A
Total Funding
26
Number of Employees
$4M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6M | 26 | 4% | N/A |
#2 | $3.8M | 26 | -10% | N/A |
#3 | $2.2M | 26 | 8% | N/A |
#4 | $3.7M | 26 | -7% | N/A |
#5 | $5.9M | 26 | -7% | N/A |